BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 24182454)

  • 21. Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade.
    Parmeland L; Gazon M; Guerin C; Argaud L; Lehot JJ; Bastien O; Allaouchiche B; Michallet M; Picot S; Bienvenu AL;
    Med Mycol; 2013 Jan; 51(1):33-7. PubMed ID: 22680978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
    Chen YC; Kuo SF; Chen FJ; Lee CH
    Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epidemiological and microbiological evaluation of nosocomial infections caused by Candida species].
    Erdem F; Tuncer Ertem G; Oral B; Karakoç E; Demiröz AP; Tülek N
    Mikrobiyol Bul; 2012 Oct; 46(4):637-48. PubMed ID: 23188577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital.
    Miranda-Zapico I; Eraso E; Hernández-Almaraz JL; López-Soria LM; Carrillo-Muñoz AJ; Hernández-Molina JM; Quindós G
    J Antimicrob Chemother; 2011 Oct; 66(10):2315-22. PubMed ID: 21795259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
    Lindberg E; Hammarström H; Ataollahy N; Kondori N
    Sci Rep; 2019 Mar; 9(1):3838. PubMed ID: 30846717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.
    Cantón E; Pemán J; Quindós G; Eraso E; Miranda-Zapico I; Álvarez M; Merino P; Campos-Herrero I; Marco F; de la Pedrosa EG; Yagüe G; Guna R; Rubio C; Miranda C; Pazos C; Velasco D;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5590-6. PubMed ID: 21930869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
    Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, virulence factors and antifungal susceptibility of Candida spp. isolated from bloodstream infections in a tertiary care hospital in Brazil.
    Canela HMS; Cardoso B; Vitali LH; Coelho HC; Martinez R; Ferreira MEDS
    Mycoses; 2018 Jan; 61(1):11-21. PubMed ID: 28940753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
    Jung SI; Shin JH; Song JH; Peck KR; Lee K; Kim MN; Chang HH; Moon CS;
    Med Mycol; 2010 Jun; 48(4):669-74. PubMed ID: 20392145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
    Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].
    Durán MT; Velasco D; Canle D; Moure R; Villanueva R
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):488-92. PubMed ID: 14572381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey.
    da Costa VG; Quesada RM; Abe AT; Furlaneto-Maia L; Furlaneto MC
    Mycopathologia; 2014 Oct; 178(3-4):243-50. PubMed ID: 25103140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Species distribution and drug susceptibilities of Candida isolates in TSARY 2010.
    Yang YL; Chen HT; Lin CC; Chu WL; Lo HJ;
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):182-6. PubMed ID: 23574935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program.
    Doi AM; Pignatari AC; Edmond MB; Marra AR; Camargo LF; Siqueira RA; da Mota VP; Colombo AL
    PLoS One; 2016; 11(1):e0146909. PubMed ID: 26808778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.